3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
37
Neoplasms
5
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Prostatic Neoplasms, Castration-Resistant
3
Metastatic Castration-Resistant Prostate Cancer
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Prostatic Diseases
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Interventions
enzalutamide
14
Docetaxel
7
radium Ra 223 dichloride
6
Abiraterone Acetate
6
Prednisone
5
darolutamide
4
abiraterone
3
olaparib
2
niraparib
2
atezolizumab
2
apalutamide
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
Rosuvastatin Calcium
1
Radium-223
1
Pluvicto
1
Pioglitazone
1
Nivolumab
1
JNJ-64619178
1
JNJ-64264681
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms, Castration-Resistant
×
abiraterone
×
Clear all
NCT06863272
2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts
NCT04844749
2024-02-05
VERACITY
Veru Inc.
Phase 3
Terminated
105 enrolled